ASH 2024: Tafasitamab Tied to Improved Progression-Free Survival in Follicular Lymphoma
When added to standard treatment, 57% reduction seen in risk for progression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.